Equities Analysts Set Expectations for Chemomab Therapeutics Ltd.’s Q1 2025 Earnings (NASDAQ:CMMB)

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) – Equities research analysts at Roth Capital issued their Q1 2025 EPS estimates for Chemomab Therapeutics in a research note issued on Friday, June 21st. Roth Capital analyst J. Wittes anticipates that the company will earn ($0.20) per share for the quarter. The consensus estimate for Chemomab Therapeutics’ current full-year earnings is ($0.90) per share. Roth Capital also issued estimates for Chemomab Therapeutics’ Q2 2025 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS and Q4 2025 earnings at ($0.20) EPS.

A number of other equities analysts have also issued reports on CMMB. Oppenheimer upgraded shares of Chemomab Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a research report on Monday, May 6th. Maxim Group raised Chemomab Therapeutics to a “strong-buy” rating in a research note on Friday, May 24th.

Chemomab Therapeutics Stock Up 2.1 %

Shares of Chemomab Therapeutics stock opened at $1.02 on Monday. The firm has a market capitalization of $11.27 million, a P/E ratio of -0.64 and a beta of 0.48. Chemomab Therapeutics has a 52 week low of $0.42 and a 52 week high of $1.50. The firm’s 50 day moving average is $0.88 and its two-hundred day moving average is $0.72.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08).

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).